We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+17.44%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$633M
AUM Growth
+$139M
Cap. Flow
+$61.7M
Cap. Flow %
9.76%
Top 10 Hldgs %
97.05%
Holding
27
New
5
Increased
8
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$71.8M
2
KRRO icon
Korro Bio
KRRO
+$9.47M
3
GHRS icon
GH Research
GHRS
+$5.48M
4
DNLI icon
Denali Therapeutics
DNLI
+$2.82M
5
TRDA icon
Entrada Therapeutics
TRDA
+$1.83M

Top Sells

Rank Stock Value
1
STOK icon
Stoke Therapeutics
STOK
+$21M
2
IMTX icon
Immatics
IMTX
+$6.91M
3
XNCR icon
Xencor
XNCR
+$2.1M
4
ARWR icon
Arrowhead Research
ARWR
+$800K
5
MPLT
MapLight Therapeutics
MPLT
+$237K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
26
DELISTED
Generation Bio
GBIO
– –
-25,000
Closed -$142K
MPLT
27
MapLight Therapeutics
MPLT
$590M
– –
-13,477
Closed -$237K
1
2

Similar funds

RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
SIC
SFE Investment Counsel Los Angeles, California $635M AUM 23.85% 1-Year Est. Return

Lynx1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Lynx1 Capital Management held 27 positions worth $633M, up 28% from $494M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Lynx1 Capital Management deployed $61.7M of net new capital in Q1 2026, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Yarrow Bioscience, Inc. Common Stock: 32,574 shares worth $973K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Stoke Therapeutics, an estimated $21M trimmed.

  • Lynx1 Capital Management's largest Q1 2026 buy was Yarrow Bioscience, Inc. Common Stock: 32,574 shares worth $973K.
  • Lynx1 Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $71.8M increase.
  • Lynx1 Capital Management's biggest Q1 2026 reduction was Stoke Therapeutics, cutting an estimated $21M.
  • Lynx1 Capital Management fully exited Arrowhead Research in Q1 2026, selling an estimated $800K.
  • Lynx1 Capital Management's ten largest holdings make up 97% of its $633M portfolio in Q1 2026.
  • Lynx1 Capital Management opened 5 new positions and closed 4 in Q1 2026.
  • Lynx1 Capital Management's portfolio value rose 28% quarter-over-quarter to $633M.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.